A new study published in the Archives of Pediatric and Adolescent Medicine shows that 10 percent of youth who become hooked on cigarettes are addicted within two days of first inhaling from a cigarette, and 25 percent are addicted within a month.

Now Viewed as a Mainstream Healthcare Market, Smoking Cessation Drugs Set to Reach $1.5 Billion. Demand Factors, Emerging Products Analyzed by Applied Data Research.

Cytos Biotechnology Enters Exclusive License Agreement With Novartis to Develop, Manufacture and Commercialize Novel Vaccine for Treatment of Nicotine Addiction.

While nicotine is highly addictive, researchers have also shown the drug to enhance learning and memory-a property that has launched efforts to develop nicotine-like drugs to treat cognitive deficits in Alzheimer's and Parkinson's diseases, schizophrenia, and attention-deficit/hyperactivity disorder.

Scientists supported by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, have for the first time identified genes that might increase a person's ability to abstain from smoking.

Physicians may some day have a new tool for tailoring smoking cessation treatments to a patient's individual genetic makeup.